Celltrion Reveals Development Achievements of Two ADC Anticancer Drugs

Presentation at the 'World ADC 2024' Conference

Celltrion disclosed the development achievements of its antibody-drug conjugate (ADC) new drug pipeline on the 6th.

Celltrion

CT-P70, presented by Celltrion at the 'World ADC 2024' conference held in San Diego, USA, from the 4th to the 7th, is an ADC therapeutic targeting solid tumors such as non-small cell lung cancer (NSCLC). It targets 'cMET' (cellular growth factor receptor), which induces tumor growth when activated in cancer cells.

Celltrion stated that CT-P70 showed effectiveness in suppressing tumors in cMET-expressing lung and stomach cancers both in vitro and in vivo, and confirmed sufficient safety in toxicity tests. Compared to existing competitive ADC drugs based on MMAE (a cytotoxic anticancer agent targeting and inhibiting microtubule protein structures to suppress tumors) payloads, CT-P70 demonstrated relatively superior therapeutic effects.

CT-P71, also disclosed, is an ADC therapeutic under development targeting solid tumors including bladder cancer. It targets Nectin-4, which is observed in tumors. Celltrion explained that CT-P71 showed efficacy in suppressing tumors of bladder, breast, and lung cancers in preclinical studies and indicated the potential for a more improved treatment option compared to existing Nectin-4 targeted ADCs.

Celltrion plans to soon enter clinical trials and complete the development of a 'best in class' new drug showing the most superior effects among therapeutics with the same mechanism.

This content was produced with the assistance of AI translation services.